Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2148 • ACR Convergence 2023
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
Josef S Smolen¹, Peter C. Taylor², Yoshiya Tanaka³, Carlos Cara⁴, Bernard Lauwerys⁵, Ricardo Xavier⁶, Jeffrey R Curtis⁷, Ted R Mikuls⁸ and Michael Weinblatt⁹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴UCB Pharma, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
Abstract Number: 2165 • ACR Convergence 2023
Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Natividad del Val del Amo³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Isabel Serrano-García⁶, Santos Castañeda⁷, Jerusalem Calvo⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucía Domínguez-Casas¹¹, Maria Camila Osorio Sanjuan¹², Carolina Díez Morrondo¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, Maria Guadalupe Mazano Canabal¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Juan Ramon De Dios²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Patricia Carreira²⁹, Juan Maria Blanco-Madrigal³¹, SARA MARIA ROJAS HERRERA³², Ignacio Brana Abascal³³, Jesus Loarce-Martos³⁴, Emilio Giner-Serret³⁵, Juan Camilo Sarmiento-Monroy³⁶, Clara ventin-Rodriguez³⁷, Marina Rodriguez-lopez³⁸, Pablo Andujar-Brazal³⁹, Julia Fernandez-Melon⁴⁰, Lilian Maria Lopez⁴¹, carlos Fernandez-Diaz⁴², Javier Loricera⁴³, Ivan Ferraz Amaro⁴⁴, Diego Ferrer⁴⁵, Ricardo Blanco⁴⁶ and On behalf of the Collaborative Group Members⁴⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Complejo Hospitalario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Division of Rheumatology, H. Puerta del Mar, Cádiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Reina Sofia University Hospital, Córdoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Division of Rheumatology, Hospital San Agustín, Avilés, Spain, ¹²Division of Rheumatology, H.U. Lozano Blesa, Zaragoza, Spain, ¹³Division of Rheumatology, Hospital de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Complejo Asistencial de Zamora, Zamora, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²H. de Sagunto, Valencia, Italy, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Araba, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³²Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Ramón y Cajal University Hospital, Madrid, Spain, ³⁵Hospital Royo Villanova, Teruel, Spain, ³⁶Hospital Clínic, Barcelona, Spain, ³⁷Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁸Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁹Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Usual interstitial pneumonia (UIP) is the most frequent, and severe ILD…
Abstract Number: 2433 • ACR Convergence 2023
Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells
Gregg Silverman¹, William Rigby², Helena Jun¹, Jasmine Shwetar¹, Katie Tumang¹, Sergei Koralov³, Ellie Ivanova¹, David Mieles¹, Sladjana Skopelia-Gardner⁴ and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²Hitchcock-Dartmouth Medicine Center, Hanover, NH, ³NYU Grossman Schoolof Medicine, New York, NY, ⁴Hitchcock-Dartmouth Medicine Center, Lebanon, NH
Background/Purpose: Biologic agents of diverse molecular mechanisms of action are approved for RA, but we do not have a full understanding of the implications of…
Abstract Number: 2503 • ACR Convergence 2023
Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes
Sofie Falkenløve Madsen¹, Mikkel Rathsach Andersen², Alexander Scheller Madrid², Signe Holm Nielsen³, Morten Karsdal³, Christian Thudium³ and Anne-Christine Bay-Jensen³, ¹University of Copenhagen, Herlev, Denmark, ²Herlev-Gentofte Hospital, Gentofte, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) and osteoarthritis (OA) are characterized by inflammation, joint swelling, stiffness, and pain. A fibroid phenotype has been identified in RA, where…
Abstract Number: 2586 • ACR Convergence 2023
A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis
Peter C. Taylor¹, Jenya Antonova², Jennifer Geis³, Katharine Dilger³, David Chernoff⁴, Diana Abdueva³, Nancy Shadick⁵ and Michael Weinblatt⁶, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA, ³Aqtual Inc., Hayward, CA, ⁴Chernoff Consulting, Sausalito, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard Medical School, Waban, MA
Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…
Abstract Number: 0012 • ACR Convergence 2023
Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity
Órla Tynan¹, Achilleas Floudas², Nuno Neto³, Michael Monaghan³, Siobhán Wade⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Dublin City University, Dublin, Ireland, ³Department of Mechanical and Manufacturing Engineering, Trinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) encompass two of the most common forms of Inflammatory Arthritis. While common pathogenic mechanisms are involved in…
Abstract Number: 0076 • ACR Convergence 2023
Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them
AASTHA KHULLAR¹, Varun Dhir², Leishangthem Bidyalaxmi¹, Chandra Bhushan Prasad³, Sankar Jayaprakash¹, Siddharth Jain⁴, Biman Saikia¹, Aman Sharma⁵, Shefali Sharma⁶, Ashok Kumar Yadav¹, Shankar Naidu¹ and Sanjay Jain⁷, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴AIIMS, Delhi, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India, ⁶PGIMER< Chandigarh, Chandigarh, India, ⁷Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Background: GMCSF producing T-cells may be implicated in the pathogenesis of autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriatic arthritis. Few…
Abstract Number: 0206 • ACR Convergence 2023
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Akhil Sood, Janice Lin and Neha Shah, Stanford University, Palo Alto, CA
Background/Purpose: Due to the use of immunosuppressants, patients with rheumatic diseases are at increased risk for Hepatitis B virus (HBV) reactivation. B-cell depleting agents and…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0397 • ACR Convergence 2023
Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire
Margaret Butler¹, Carlos Aude², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Elevated BMI has been previously associated with lower RA remission rates and underascertainment of swollen joint counts.1,2 However, a knowledge gap persists regarding the…
Abstract Number: 0414 • ACR Convergence 2023
Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe
Douglas White¹, Aditi Kadakia², Oliver Howell³, Sander Strengholt⁴, Emily Goddard³, Sophie Barlow³ and Tsutomu Takeuchi⁵, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie B.V., Mijdrecht, Utrecht, Netherlands, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing swelling, stiffness, and pain that impact a patient's quality of life. EULAR treatment…
Abstract Number: 0431 • ACR Convergence 2023
Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Rodolfo Jiménez-Soto¹, Luis llorente², Guadalupe Lima¹, Luisa Alanis Saenz¹, Amairani Gomez Rodriguez¹, Hilda Marin Lopez¹, Erik Cimé-Aké¹ and Juan Jakez-Ocampo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…
Abstract Number: 0448 • ACR Convergence 2023
Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study
Ashit Syngle¹, Inderjeet verma², Nidhi Garg³, Kanchan Chauhan¹, Sapna Patyal¹ and Devaansh Syngle⁴, ¹Healing Touch City Clinic, Chandigarh, India, ²Maharishi Markandeshwar University, Mulana, India, ³Chitkara, Rajpura, India, ⁴Healing Touch Foundation, Chandigarh, India
Background/Purpose: RA patients have at least twice the risk of CVD. In fact, CVD is the leading cause of morbidity and premature mortality in RA.…
Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Ashmia Saif¹, Priyanka Dongare², Meghan Beard³, Yunhan Liao⁴, Xiaoyue Zhang⁴, Qingping Yao⁵ and Asha Patnaik⁶, ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University Hospital, Highland, NY, ³Stony Brook Southampton, Moriches, NY, ⁴Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁵Stony Brook University, Stony Brook, NY, ⁶Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…
Abstract Number: 0772 • ACR Convergence 2023
MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Klein¹, Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Dana Ascherman⁶, Gary Kunkel⁷, Grant Cannon⁸, Paul Monach⁹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹⁰ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The gain of function MUC5B rs35705950 promoter variant is the strongest genetic risk factor for the development of RA-ILD (specific to a usual interstitial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].